A multicenter, randomized trial conducted by de Zeeuw’s team showed that compared to 111 DN patients treated by placebo, 221 patients with DN had a secondary decline in albuminuria given CCX140-B, a selective inhibitor of CCR2, based on standard care with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) (48). This evidence concerns the gene CCR2 and liver dysplastic nodule.